Protein isoprenylation regulates secretion of matrix metalloproteinase 1 from rheumatoid synovial fibroblasts: Effects of statins and farnesyl and geranylgeranyl transferase inhibitors

Authors:

Abstract
Objective: To determine whether protein prenylation (farnesyl/geranylgeranylation) regulates matrix metalloproteinase (MMP) secretion from rheumatoid arthritis (RA) synovial fibroblasts (RASFs), and whether MMP‐1 secretion can be regulated by statins or prenyltransferase inhibitors via effects mediated by ERK, JNK, and NF‐κB.Methods: RASFs obtained from patients during elective knee replacement surgery were assessed by immunoblotting and/or enzyme‐linked immunosorbent assay for secretion of MMP‐1 and MMP‐13 in the presence of tumor necrosis factor α (TNFα), interleukin‐1β (IL‐1β), statins, the farnesyl transferase (FT) inhibitor FTI‐276 and geranylgeranyl transferase inhibitor GGTI‐298, and prenyl substrates (farnesyl pyrophosphate [FPP] and geranylgeranyl pyrophosphate [GGPP]). Activities of JNK and ERK were determined by phosphoimmunoblotting, and NF‐κB activation was determined by nuclear translocation of the p65 component.Results: FTI‐276, but not statins, inhibited RASF secretion of MMP‐1, but not MMP‐13, following induction with TNFα (P = 0.0007) or IL‐1β (P = 0.006). Loading RASFs with FPP to promote farnesylation enhanced MMP‐1 secretion. FTI‐276 inhibited activation of JNK (P < 0.05) and NF‐κB (P = 0.02), but not ERK. In contrast, GGTI‐298 enhanced, while GGPP inhibited, MMP‐1 secretion. FTI‐276 and GGTI‐298 together had no effect on MMP‐1 secretion. Stimulation of RASFs with TNFα or IL‐1β led to increased expression and activity of FT.Conclusion: Protein farnesylation is required for expression and secretion of MMP‐1 from RASFs, via effects on JNK and NF‐κB. The ability of cytokines to stimulate the expression and activity of FT suggests that FT may be increased in the rheumatoid joint. In contrast, geranylgeranylation down‐regulates MMP‐1 expression. Statins simultaneously inhibit farnesylation and geranylgeranylation, and in consequence do not inhibit MMP‐1 secretion. The ability of FTI‐276 to inhibit MMP‐1 secretion suggests a potential therapeutic strategy in RA.

This publication has 69 references indexed in Scilit: